Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus [5]

Annals of the Rheumatic Diseases

Volumn 66, Issue 12, 2007, Pages 1688-

  Bonilla, Eduardo ^a,b   Lee, Y Y ^a   Phillips, P E ^a   Perl, A ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GLUCOSE; INSULIN LISPRO; METHOTREXATE; PREDNISONE;

ADULT; ANAMNESIS; CASE REPORT; DIET THERAPY; DISEASE COURSE; DOSE RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LETTER; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 36749076570     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.072256     Document Type: Letter

References (4)

1. Spencer-Green G. Etanercept: update on therapeutic use. Ann Rheum Dis, 2000;59(suppl 1), i46-i49.
2. Mahony SM, Tisdale MJ. Metabolic effects of tumor necrosis factor alpha in NMRI mice. Br J Cancer 1990;61:514-19.
3. Satomi N, Sakurai A, Haranaka K. Relationship of hypoglycemia to tumor necrosis factor production and anitumor activity. J Natl Cancer Inst 1985;74:1255-60.
4. Gonzalez-Gay MA, DeMatias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Marin J, et al. Anti-tumor necrosis factor alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:83-6.